Last reviewed · How we verify

NCT07352384: NeuroFace

Evaluation of the Efficacy of Neuromodulation in the Control of Chronic Orofacial Pain

ENROLLING BY INVITATION NA Last updated 20 February 2026
What this trial tests

NA trial testing Active Neuromodulation (tDCS or TMS) in Orofacial Pain in 50 participants. Enrolling by invitation.

Timeline
1 November 2025
Primary endpoint
1 May 2026
1 August 2026

Quick facts

Lead sponsorEgas Moniz - Cooperativa de Ensino Superior, CRL
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment50
Start date1 November 2025
Primary completion1 May 2026
Estimated completion1 August 2026
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Egas Moniz - Cooperativa de Ensino Superior, CRL — full company profile →

Who can join

Adults 18 to 75, any sex, with Orofacial Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic orofacial pain significantly affects patients' quality of life, compromising essential functions such as chewing and speech. Although conventional treatments are available, many patients do not achieve adequate and lasting relief. This project investigates the effectiveness of neuromodulation techniques, namely transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), as innovative therapeutic alternatives for the control of chronic orofacial pain. The study will be conducted in adult patients diagnosed with orofacial pain. Participants will be divided into two groups: one group will receive active neuromodulation (tDCS or TMS) and the other a sham treatment (placebo). Sessions will take place daily over two weeks. Assessments will include pain intensity, pain pressure threshold, masticatory function, and bite strength, in order to observe any functional changes. The group undergoing neuromodulation is expected to show a significant reduction in pain levels and improvements in quality of life compared to the placebo group. This study could support the adoption of neuromodulation as a complementary approach in the treatment of chronic orofacial pain, offering an effective and non-invasive alternative for patients who do not respond to conventional treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Orofacial Pain

Currently open trials in the same condition.

Other Egas Moniz - Cooperativa de Ensino Superior, CRL trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07352384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing